Articles found by an AI-assisted PubMed search that may be missing from CancerImmunoDB, shared so that curators and users can see what is being considered.
Why this exists: the database holds only about 10 articles a year for 2021–2024, and a plain PubMed search cannot judge whether a paper fits the scope.
| Year | Screened | Likely relevant |
|---|---|---|
| 2026 | 99 | 61 |
| 2025 | 100 | 81 |
| 2024 | 98 | 72 |
| 2023 | 92 | 45 |
| 2022 | 100 | 52 |
| 2021 | 85 | 49 |
360 articles shown. “In the database” counts the entries the database already has for each drug the AI named (cell line / animal / patient).
| PMID | Year | Article | Drugs | Study type | Cancer type | In the database | Curator status |
|---|---|---|---|---|---|---|---|
| 40004078 | 2025 | Immunogenic Cell Death Inducers in Cancer Immunotherapy to Turn Cold Tumors into Hot Tumors. International journal of molecular sciences Likely relevant The study tests anthracycline chemotherapeutics (mitoxantrone and doxorubicin) on tumor spheroids and in vivo models and measures their effects on MHC class I, cytokine production, immune cell recruitment, and PD-L1 expression. | mitoxantrone; doxorubicin | Mixed | neuroblastoma | mitoxantrone 0/0/0; doxorubicin 22/9/0 | Awaiting curator check |
| 40023845 | 2025 | The NF1 tumor suppressor regulates PD-L1 and immune evasion in melanoma. Cell reports Likely relevant The study examines NF1 loss in melanoma cell lines and tests anti-PD-1/PD-L1 antibodies in co-culture experiments measuring resistance to T cell killing. | anti-PD-1; anti-PD-L1 | Cell line | melanoma | anti-PD-1 14/36/0; anti-PD-L1 0/15/0 | Awaiting curator check |
| 40038278 | 2025 | PARP inhibitor radiosensitization enhances anti-PD-L1 immunotherapy through stabilizing chemokine mRNA in small cell lung cancer. Nature communications Likely relevant The study evaluates PARP inhibitors in combination with radiotherapy and anti-PD-L1 in SCLC cell lines, PDX, and mice, measuring chemokine expression and T cell infiltration. | olaparib; talazoparib; veliparib; anti-PD-L1 | Mixed | small cell lung cancer | olaparib 19/5/0; talazoparib 0/0/0; veliparib 0/0/0; anti-PD-L1 0/15/0 | Awaiting curator check |
| 40068706 | 2025 | Irreversible electroporation combined with PD-L1/IL-6 dual blockade promotes anti-tumor immunity via cDC2/CD4+T cell axis in MHC-I deficient pancreatic cancer. Cancer letters Likely relevant The study evaluates PD-L1 and IL-6 blockade therapies in clinical samples and murine models, measuring changes in CD4+ T cell polarization, dendritic cell activation, and NK cell responses. | PD-L1 blockade; IL-6 blockade | Mixed | pancreatic cancer | PD-L1 blockade 0/4/0; IL-6 blockade 0/0/0 | Awaiting curator check |
| 40075237 | 2025 | Targeting both death and paracaspase domains of MALT1 with antisense oligonucleotides overcomes resistance to immune-checkpoint inhibitors. Nature cancer Likely relevant The study tests MALT1 antisense oligonucleotides in patient-derived tumor cells and mouse models, measuring PD-L1 expression and macrophage polarization. | MALT1 antisense oligonucleotides; immune-checkpoint inhibitors | Mixed | solid tumors | MALT1 antisense oligonucleotides 0/0/0; immune-checkpoint inhibitors 0/0/0 | Awaiting curator check |
| 40083936 | 2025 | The TMBIM1-YBX1 axis orchestrates MDSC recruitment and immunosuppressive microenvironment in pancreatic cancer. Theranostics Likely relevant The study tests genetic knockdown combined with anti-PD-1 antibody treatment in a mouse xenograft model and measures CD8+ T-cell activation and MDSC infiltration. | anti-PD-1 antibody | Animal | pancreatic cancer | anti-PD-1 antibody 0/2/0 | Awaiting curator check |
| 40087780 | 2025 | Combination therapy with Chicoric acid and PD-1/PD-L1 blockade improves the immunotherapy response in patient-derived ovarian cancer xenograft model. Cell communication and signaling : CCS Likely relevant The study tests chicoric acid and PD-1/PD-L1 blockade in a patient-derived xenograft model and measures immune cell proliferation and T cell infiltration. | Chicoric acid; aPD-1; aPD-L1 | Animal | ovarian cancer | Chicoric acid 0/0/0; aPD-1 0/0/0; aPD-L1 0/0/0 | Awaiting curator check |
| 40091844 | 2025 | Epigenetic therapy sensitizes anti-PD-1 refractory head and neck cancers to immunotherapy rechallenge. The Journal of clinical investigation Likely relevant The clinical trial evaluates 5-azacytidine combined with durvalumab and tremelimumab in patients, measuring IFN-gamma, PD-L1, and immune cell infiltrates. | 5-azacytidine; durvalumab; tremelimumab | Patient | head and neck squamous cell carcinoma | 5-azacytidine 8/0/0; durvalumab 0/0/2; tremelimumab 0/0/0 | Awaiting curator check |
| 40102596 | 2025 | CAR-NK cell therapy combined with checkpoint inhibition induces an NKT cell response in glioblastoma. British journal of cancer Likely relevant The study tests CAR-NK cell therapy combined with anti-PD-1 checkpoint blockade in mouse tumor models and measures immune microenvironment changes including T and NKT cell infiltration. | NK-92/5.28.z; anti-PD-1 | Animal | glioblastoma | NK-92/5.28.z 0/0/0; anti-PD-1 14/36/0 | Awaiting curator check |
| 40125618 | 2025 | Methionine Metabolism Dictates PCSK9 Expression and Antitumor Potency of PD-1 Blockade in MSS Colorectal Cancer. Advanced science (Weinheim, Baden-Wurttemberg, Germany) Likely relevant The study tests anti-PD-1 blockade and 5-FU chemotherapy in tumor-bearing mice and reports the effect on CD8+ T cell infiltration. | anti-PD-1; 5-fluorouracil | Animal | colorectal cancer | anti-PD-1 14/36/0; 5-fluorouracil 10/5/3 | Awaiting curator check |
| 40168999 | 2025 | TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumors. Cell reports. Medicine Likely relevant A clinical phase 1 study evaluating the combination of MTL-CEBPA and pembrolizumab in patients, measuring changes in immune cell infiltration and myeloid cells. | MTL-CEBPA; pembrolizumab | Patient | solid tumors | MTL-CEBPA 0/0/0; pembrolizumab 0/0/16 | Awaiting curator check |
| 40203792 | 2025 | TRx0237 induces apoptosis and enhances anti-PD-1 immunotherapeutic efficacy in anaplastic thyroid Cancer. International immunopharmacology Likely relevant The study tests TRx0237 and anti-PD-1 in xenograft and organoid models and measures the drug's effect on PD-L1 expression. | TRx0237; anti-PD-1 | Animal | anaplastic thyroid cancer | TRx0237 0/0/0; anti-PD-1 14/36/0 | Awaiting curator check |
| 40213972 | 2025 | Targeting PFKFB4 Biomimetic Codelivery System Synergistically Enhances Ferroptosis to Suppress Small Cell Lung Cancer and Augments the Efficacy of Anti-PD-L1 Immunotherapy. Advanced science (Weinheim, Baden-Wurttemberg, Germany) Likely relevant The study tests a drug co-delivery system (paclitaxel and siPFKFB4) combined with anti-PD-L1 antibodies in SCLC models and reports changes in immune cell infiltration and cytokine secretion. | paclitaxel; siPFKFB4; anti-PD-L1 | Animal | small cell lung cancer | paclitaxel 21/5/8; siPFKFB4 0/0/0; anti-PD-L1 0/15/0 | Awaiting curator check |
| 40215778 | 2025 | NCOA3 impairs the efficacy of anti-PD-L1 therapy via HSP90α/EZH2/CXCL9 axis in colon cancer. International immunopharmacology Likely relevant The study experimentally tests anti-PD-L1 and the small molecule inhibitor SI-2 in colon cancer models and measures effects on CD8+ T cell infiltration and CXCL9 expression. | anti-PD-L1; SI-2 | Mixed | colon cancer | anti-PD-L1 0/15/0; SI-2 0/0/0 | Awaiting curator check |
| 40221409 | 2025 | Addition of metformin to anti-PD-1/PD-L1 drugs activates anti-tumor immune response in peripheral immune cells of NSCLC patients. Cell death & disease Likely relevant The study tests metformin combined with anti-PD-1/PD-L1 drugs using cancer-immune cell co-cultures and patient peripheral blood mononuclear cells, measuring immune pathway activation and macrophage polarization. | metformin; anti-PD-1/PD-L1 | Mixed | non-small cell lung cancer | metformin 0/0/0; anti-PD-1/PD-L1 0/0/0 | Awaiting curator check |
| 40246583 | 2025 | Shp-1 regulates the activity of low-affinity T cells specific to endogenous self-antigen during melanoma tumor growth and drives resistance to immune checkpoint inhibition. Journal for immunotherapy of cancer Likely relevant The study administers a Shp-1 inhibitor (TPI-1) with or without immune checkpoint inhibition in tumor-bearing mice and analyzes changes in tumor immune infiltrate and T cell phenotypes. | TPI-1; immune checkpoint inhibitor | Animal | melanoma | TPI-1 0/0/0; immune checkpoint inhibitor 0/0/0 | Awaiting curator check |
| 40262436 | 2025 | An antibody targeting an immune checkpoint molecule BTN2A2 enhances anti-tumor immunity. Neoplasia (New York, N.Y.) Likely relevant The study tests an anticancer agent (anti-BTN2A2 monoclonal antibody) in mouse models of cancer and measures its effects on multiple immune cell infiltrates and cytokine expressions. | anti-BTN2A2 monoclonal antibody | Animal | pancreatic cancer and glioma | anti-BTN2A2 monoclonal antibody 0/0/0 | Awaiting curator check |
| 40269245 | 2025 | Fangchinoline-mediated autophagy inhibition amplifies antigen presentation and PD-1 blockade efficacy in lung cancer. Acta pharmacologica Sinica Likely relevant The study tests fangchinoline and anti-PD-1 therapy in vitro and in vivo, measuring MHC-I expression and CD8+ T cell-mediated cytotoxicity. | fangchinoline; anti-PD-1 | Mixed | lung cancer | fangchinoline 0/0/0; anti-PD-1 14/36/0 | Awaiting curator check |
| 40280928 | 2025 | T-bet+CD8+ T cells govern anti-PD-1 responses in microsatellite-stable gastric cancers. Nature communications Likely relevant The study experimentally tests anti-PD-1 therapy in humanized mouse models, assessing its effect on T-bet+ CD8+ T cells and anti-tumor immunity. | anti-PD-1 | Animal | gastric cancer | anti-PD-1 14/36/0 | Awaiting curator check |
| 40294469 | 2025 | Dual cytokine-engineered macrophages rejuvenate the tumor microenvironment and enhance anti-PD-1 therapy in renal cell carcinoma. International immunopharmacology Likely relevant The study tests dual-cytokine-engineered macrophages in combination with anti-PD-1 therapy in tumor-bearing mice, measuring changes in tumor microenvironment immune cell populations. | anti-PD-1 | Animal | renal cell carcinoma | anti-PD-1 14/36/0 | Awaiting curator check |
| 40329005 | 2025 | CD200R blockade enhances anti-tumor immunity by unleashing NK and CD8+ T cells in tumor. Acta pharmacologica Sinica Likely relevant The study experimentally tests CD200R genetic ablation and antibody blockade, alone and combined with anti-PD-1/anti-PD-L1, in tumor-bearing mice, measuring effects on NK and CD8+ T cell exhaustion and function. | anti-CD200R antibody; anti-PD-1; anti-PD-L1 | Animal | colon cancer, fibrosarcoma, lung cancer, mammary cancer | anti-CD200R antibody 0/0/0; anti-PD-1 14/36/0; anti-PD-L1 0/15/0 | Awaiting curator check |
| 40345706 | 2025 | Defects in the necroptosis machinery are a cancer resistance mechanism to checkpoint inhibitor immunotherapy. Journal for immunotherapy of cancer Likely relevant The study experimentally tests immune checkpoint inhibitors and azacytidine in murine tumor models and measures their effects on dendritic cells and CD8+ T cell responses. | anti-PD-1; anti-CTLA-4; azacytidine | Animal | melanoma | anti-PD-1 14/36/0; anti-CTLA-4 1/10/7; azacytidine 12/2/1 | Awaiting curator check |
| 40346531 | 2025 | N-glycosylation of PD-L1 modulates the efficacy of immune checkpoint blockades targeting PD-L1 and PD-1. Molecular cancer Likely relevant The study tests anti-PD-L1 and anti-PD-1 antibodies on human cancer cell lines expressing specific PD-L1 glycosylation mutants and measures human CD8+ T cell activation and cytotoxicity. | anti-PD-L1 antibodies; anti-PD-1 antibodies | Cell line | breast cancer, melanoma, lung carcinoma | anti-PD-L1 antibodies 0/0/0; anti-PD-1 antibodies 0/0/0 | Awaiting curator check |
| 40348005 | 2025 | Targeting of COPⅠ elicits CD8+ T cell-mediated anti-tumor immunity and suppresses growth of intrahepatic cholangiocarcinoma. Cancer letters Likely relevant The study tests genetic and pharmacological inhibition of COPI and anti-PD-1 therapy in mouse models, measuring T cell presence and immune activation via the STING pathway. | anti-PD-1 | Animal | intrahepatic cholangiocarcinoma | anti-PD-1 14/36/0 | Awaiting curator check |
| 40353734 | 2025 | Sitravatinib Targets TYRO3 to Augment the Antitumor Immune Response of PD-1 Blockade in Hepatocellular Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research Likely relevant Investigates the immunomodulatory activity and efficacy of sitravatinib combined with PD-1 blockade in cell lines, mouse models, and a patient. | sitravatinib; PD-1 blockade | Mixed | hepatocellular carcinoma | sitravatinib 0/0/0; PD-1 blockade 0/0/0 | Awaiting curator check |